Cargando…

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alessandrino, Emilio Paolo, Porta, Matteo G Della, Malcovati, Luca, Jackson, Christopher H, Pascutto, Cristiana, Bacigalupo, Andrea, Teresa van Lint, Maria, Falda, Michele, Bernardi, Massimo, Onida, Francesco, Guidi, Stefano, Iori, Anna Paola, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Angelucci, Emanuele, Oneto, Rosi, Ripamonti, Francesco, Rambaldi, Alessandro, Bosi, Alberto, Cazzola, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736162/ https://www.ncbi.nlm.nih.gov/pubmed/23606215 http://dx.doi.org/10.1002/ajh.23458

Ejemplares similares

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Outcome of Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioninig Regimen in Patients With Idiopathic Myelofibrosis: the G.I.T.M.O. Experience
por: Patriarca, Francesca, et al.
Publicado: (2010)

Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients
por: Rambaldi, A, et al.
Publicado: (2012)

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
por: Mangiacavalli, Silvia, et al.
Publicado: (2013)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo
por: Todisco, E, et al.
Publicado: (2013)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Molecular genetics in clinical decision making for patients with myelodysplastic syndromes or related disorders
por: Cazzola, Mario
Publicado: (2018)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001‐2012
por: Bacigalupo, Andrea, et al.
Publicado: (2018)

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
por: Gerstung, Moritz, et al.
Publicado: (2015)

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
por: Bersanelli, Matteo, et al.
Publicado: (2021)

Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?
por: Cazzola, Mario, et al.
Publicado: (2023)

Emigration Effects Induced by Radio Frequency Treatment to Dates Infested by Carpophilus hemipterus
por: Rosi, Marzia Cristiana, et al.
Publicado: (2019)

Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants
por: Metafuni, Elisabetta, et al.
Publicado: (2018)

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
por: Guzzi, Nicola, et al.
Publicado: (2022)

The U2AF1(S34F) mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
por: Yip, Bon Ham, et al.
Publicado: (2017)

Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy
por: Pinto, Valeria, et al.
Publicado: (2015)

New Treatments for Myelodysplastic Syndromes
por: D’Alò, Francesco, et al.
Publicado: (2010)

Factors affecting prognosis in myelofibrosis
por: Onida, Francesco
Publicado: (2009)

Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
por: Rogliani, Paola, et al.
Publicado: (2022)

Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score
por: Rogliani, Paola, et al.
Publicado: (2022)

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
por: Dolatshad, H, et al.
Publicado: (2015)

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
por: Dolatshad, H, et al.
Publicado: (2015)

Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
por: Malagola, Michele, et al.
Publicado: (2023)

Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes
por: Santini, Valeria, et al.
Publicado: (2011)

Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
por: Cazzola, Mario, et al.
Publicado: (2017)

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways
por: Calzetta, Luigino, et al.
Publicado: (2018)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Treatable Mechanisms in Asthma
por: Cazzola, Mario, et al.
Publicado: (2021)

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
por: Cazzola, Mario, et al.
Publicado: (2021)

Sex differences in adult asthma and COPD therapy: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2022)

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience
por: Mossuto, Sandra, et al.
Publicado: (2020)

Colour Preference of the Deer Ked Lipoptena Fortisetosa (Diptera: Hippoboscidae)
por: Andreani, Annalisa, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?
por: Farina, Mirko, et al.
Publicado: (2020)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes
por: Vallelonga, Veronica, et al.
Publicado: (2023)

Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an “Old-fashioned” Drug be Effective?
por: Riva, Marta, et al.
Publicado: (2023)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l4513eop32658769lgj8sqbe07